These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2485069)

  • 1. In vitro inhibition of human renin by statine-containing tripeptide renin inhibitor (ES-1005).
    Kokubu T; Hiwada K; Murakami E; Muneta S; Morisawa Y; Yabe Y; Koike H; Iijima Y
    J Cardiovasc Pharmacol; 1987; 10 Suppl 7():S88-90. PubMed ID: 2485069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statine-containing dipeptide and tripeptide inhibitors of human renin.
    Kokubu T; Hiwada K; Nagae A; Murakami E; Morisawa Y; Yabe Y; Koike H; Iijima Y
    Hypertension; 1986 Jun; 8(6 Pt 2):II1-5. PubMed ID: 3087874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly potent and specific inhibitors of human renin.
    Kokubu T; Hiwada K; Murakami E; Imamura Y; Matsueda R; Yabe Y; Koike H; Iijima Y
    Hypertension; 1985; 7(3 Pt 2):I8-11. PubMed ID: 2987128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly potent and specific inhibitors of human renin.
    Kokubu T; Hiwada K; Sato Y; Iwata T; Imamura Y; Matsueda R; Yabe Y; Kogen H; Yamazaki M; Iijima Y
    Biochem Biophys Res Commun; 1984 Feb; 118(3):929-33. PubMed ID: 6422931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A highly potent and long-acting oral inhibitor of human renin.
    Hiwada K; Kokubu T; Murakami E; Muneta S; Morisawa Y; Yabe Y; Koike H; Iijima Y
    Hypertension; 1988 Jun; 11(6 Pt 2):708-12. PubMed ID: 3134306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro and in vivo inhibition of renin by a thiazolylalanyl cyclostatine derivative].
    Muneta S
    Nihon Jinzo Gakkai Shi; 1989 Aug; 31(8):865. PubMed ID: 2512401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine.
    Boger J; Payne LS; Perlow DS; Lohr NS; Poe M; Blaine EH; Ulm EH; Schorn TW; LaMont BI; Lin TY
    J Med Chem; 1985 Dec; 28(12):1779-90. PubMed ID: 3906131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a potent inhibitor of subprimate and primate renins.
    Wood JM; Mah SC; Baum HP; de Gasparo M; Cumin F; Rüeger H; Nussberger J
    J Pharmacol Exp Ther; 1990 May; 253(2):513-7. PubMed ID: 2110974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pepstatin inhibition mechanism.
    Marciniszyn J; Hartsuck JA; Tang J
    Adv Exp Med Biol; 1977; 95():199-210. PubMed ID: 339690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of porcine pepsin by two substrate analogues containing statine. The effect of histidine at the P2 subsite on the inhibition of aspartic proteinases.
    Maibaum J; Rich DH
    J Med Chem; 1988 Mar; 31(3):625-9. PubMed ID: 3126296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of structure-activity relationships in renin substrate analogue inhibitory peptides.
    Hui KY; Carlson WD; Bernatowicz MS; Haber E
    J Med Chem; 1987 Aug; 30(8):1287-95. PubMed ID: 3302256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CGP 38 560: orally active, low-molecular-weight renin inhibitor with high potency and specificity.
    Wood JM; Criscione L; de Gasparo M; Bühlmayer P; Rüeger H; Stanton JL; Jupp RA; Kay J
    J Cardiovasc Pharmacol; 1989 Aug; 14(2):221-6. PubMed ID: 2476594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mode of inhibition of acid proteases by pepstatin.
    Marciniszyn J; Hartsuck JA; Tang J
    J Biol Chem; 1976 Nov; 251(22):7088-94. PubMed ID: 993206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the renin inhibitor H77 on the pressor responses to injected pig, rat and dog renins in vivo.
    Oldham AA; Arnstein MJ; Major JS; Clough DP
    J Hypertens; 1983 Aug; 1(2):191-5. PubMed ID: 6397517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin inhibitors containing hydrophilic groups. Tetrapeptides with enhanced aqueous solubility and nanomolar potency.
    Bock MG; DiPardo RM; Evans BE; Freidinger RM; Rittle KE; Payne LS; Boger J; Whitter WL; LaMont BI; Ulm EH
    J Med Chem; 1988 Oct; 31(10):1918-23. PubMed ID: 3050088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of potent substrate-analogue inhibitors of canine renin.
    Hui KY; Siragy HM; Haber E
    Int J Pept Protein Res; 1992 Aug; 40(2):152-60. PubMed ID: 1446972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Syntheses and biological activities of renin inhibitors containing statine analogues.
    Nishi T; Saito F; Nagahori H; Kataoka M; Morisawa Y; Yabe Y; Sakurai M; Higashida S; Shoji M; Matsushita Y
    Chem Pharm Bull (Tokyo); 1990 Jan; 38(1):103-9. PubMed ID: 2110866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly potent and specific inhibitors of human renin.
    Sham HL; Stein H; Rempel CA; Cohen J; Plattner JJ
    FEBS Lett; 1987 Aug; 220(2):299-301. PubMed ID: 3111889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin inhibitors. Statine-containing tetrapeptides with varied hydrophobic carboxy termini.
    Bock MG; DiPardo RM; Evans BE; Rittle KE; Boger J; Poe M; LaMont BI; Lynch RJ; Ulm EH; Vlasuk GP
    J Med Chem; 1987 Oct; 30(10):1853-7. PubMed ID: 3309316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRI-1314: an orally effective inhibitor of human renin.
    Etoh Y; Miyazaki M; Saitoh H; Toda N
    Jpn J Pharmacol; 1993 Sep; 63(1):109-19. PubMed ID: 8271523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.